Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1529–1532. doi: 10.1038/bjc.1996.288

Clinical significance of serum CYFRA 21-1 in gastric cancer.

B Nakata 1, Y S Chung 1, Y Kato 1, M Ogawa 1, Y Ogawa 1, A Inui 1, K Maeda 1, T Sawada 1, M Sowa 1
PMCID: PMC2074562  PMID: 8664124

Abstract

We studied the clinical significance of the soluble cytokeratin 19 fragment detected with monoclonal antibody CYFRA 21-1 in the sera of patients with histologically proven gastric cancer. Sera of 110 patients with gastric cancer were analysed for CYFRA 21-1 levels by a two-step sandwich enzyme immunoassay. There were no significant differences between CYFRA 21-1 levels and the histotype, depth of invasion or vessel invasion. However, CYFRA 21-1 was significantly higher in the presence of peritoneal metastases, liver metastases and extensive nodal involvement. When the positive cut-off value was defined as 5 ng ml-1, the CYFRA 21-1 in the stage IV and recurrent cases was 55.6% and 66.7%, respectively, which was as high as carcinoembryonic antigen (CEA) and greater than carbohydrate antigen 19-9 (CA 19-9). The positivities in stage I/II and III were zero and 5.9%, respectively, and false-positive rate in 76 patients with benign gastrointestinal disorders was 2.6%. There appeared to be no correlation between CYFRA 21-1 and CEA or CA 19-9. The patients with above 5 n ml-1 of CYFRA 21-1 had a significantly poorer prognosis. Multivariate analysis indicated that CYFRA 21-1 was an independent prognostic factor, while CEA and CA 19-9 failed to be of prognostic value. In conclusion, CYFRA 21-1 is a reliable tumour marker for gastic cancer in predicting very advanced cases, recurrence of the disease and overall poor prognosis.

Full text

PDF
1529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodenmüller H., Donié F., Kaufmann M., Banauch D. The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers. 1994 Apr-Jun;9(2):70–74. doi: 10.1177/172460089400900202. [DOI] [PubMed] [Google Scholar]
  2. Bodenmüller H., Ofenloch-Hähnle B., Lane E. B., Dessauer A., Böttger V., Donié F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers. 1994 Apr-Jun;9(2):75–81. doi: 10.1177/172460089400900203. [DOI] [PubMed] [Google Scholar]
  3. Bonfrer J. M., Gaarenstroom K. N., Kenter G. G., Korse C. M., Hart A. A., Gallee M. P., Helmerhorst T. J., Kenemans P. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol. 1994 Dec;55(3 Pt 1):371–375. doi: 10.1006/gyno.1994.1309. [DOI] [PubMed] [Google Scholar]
  4. Broers J. L., Ramaekers F. C., Rot M. K., Oostendorp T., Huysmans A., van Muijen G. N., Wagenaar S. S., Vooijs G. P. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988 Jun 1;48(11):3221–3229. [PubMed] [Google Scholar]
  5. Debus E., Moll R., Franke W. W., Weber K., Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol. 1984 Jan;114(1):121–130. [PMC free article] [PubMed] [Google Scholar]
  6. Doweck I., Barak M., Greenberg E., Uri N., Kellner J., Lurie M., Gruener N. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):177–181. doi: 10.1001/archotol.1995.01890020039009. [DOI] [PubMed] [Google Scholar]
  7. Ferdeghini M., Gadducci A., Annicchiarico C., Prontera C., Malagnino G., Castellani C., Facchini V., Bianchi R. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res. 1993 Sep-Oct;13(5C):1841–1844. [PubMed] [Google Scholar]
  8. Molina R., Agusti C., Filella X., Jo J., Joseph J., Giménez N., Ballesta A. M. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol. 1994;15(6):318–325. doi: 10.1159/000217908. [DOI] [PubMed] [Google Scholar]
  9. Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
  10. Pujol J. L., Grenier J., Daurès J. P., Daver A., Pujol H., Michel F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993 Jan 1;53(1):61–66. [PubMed] [Google Scholar]
  11. Steinert P. M., Roop D. R. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem. 1988;57:593–625. doi: 10.1146/annurev.bi.57.070188.003113. [DOI] [PubMed] [Google Scholar]
  12. Stieber P., Bodenmüller H., Banauch D., Hasholzner U., Dessauer A., Ofenloch-Hähnle B., Jaworek D., Fateh-Moghadam A. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem. 1993 Aug;26(4):301–304. doi: 10.1016/0009-9120(93)90129-t. [DOI] [PubMed] [Google Scholar]
  13. Stieber P., Hasholzner U., Bodenmüller H., Nagel D., Sunder-Plassmann L., Dienemann H., Meier W., Fateh-Moghadam A. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993 Aug 1;72(3):707–713. doi: 10.1002/1097-0142(19930801)72:3<707::aid-cncr2820720313>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  14. Sugama Y., Kitamura S., Kawai T., Ohkubo A., Hasegawa S., Kuriyama T., Kato H., Fukuoka M., Ohkawa J. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994 Nov;85(11):1178–1184. doi: 10.1111/j.1349-7006.1994.tb02925.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sundström B. E., Nathrath W. B., Stigbrand T. I. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem. 1989 Dec;37(12):1845–1854. doi: 10.1177/37.12.2479674. [DOI] [PubMed] [Google Scholar]
  16. Takada M., Masuda N., Matsuura E., Kusunoki Y., Matui K., Nakagawa K., Yana T., Tuyuguchi I., Oohata I., Fukuoka M. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 1995 Jan;71(1):160–165. doi: 10.1038/bjc.1995.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. van der Gaast A., Schoenmakers C. H., Kok T. C., Blijenberg B. G., Cornillie F., Splinter T. A. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer. 1994 Mar;69(3):525–528. doi: 10.1038/bjc.1994.95. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES